Akero
Eva Rankers has extensive experience in accounts payable, with a background in managing vendor invoices, employee expense reports, reconciliation of accounts, and processing 1099s. Eva has worked at companies like Akero Therapeutics, Adamas Pharmaceuticals, Inc., Sub-One Technology, and Tosoh America, Inc. Eva also has a solid educational background from Saint Paul College in the Philippines and Maryknoll College-Manila.
Akero
1 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.